Open access
Aug 2026
Foretinib triggers immunogenic cell death and enhances efficacy of anti-CD47 immunotherapy in colorectal cancer
The dual-target c-Met/VEGFR kinase inhibitor foretinib reshapes tumor immune microenvironment (TIME) by inducing immunogenic cell death (ICD) and the combination of foretinib with anti-CD47 antibody significantly inhibits tumor growth in colon cancer model.
Lin Li, Nannan Zhu, Tao Zhu et al.
· Neoplasia · 0 citations